Tresiba is used to treat type 1 and type 2 diabetes in adults and children aged 1 to 18 years of age.
The medicine can only be obtained with a prescription.
Diabetes is a disease in which the body does not produce enough insulin to control the level of blood sugar or when the body is unable to use insulin effectively. Tresiba is a replacement insulin that is very similar to the natural insulin with a difference that it is absorbed more slowly in the body and takes longer to reach its target. This means that Tresiba has a long duration of action. Tresiba acts in the same way as naturally produced insulin and helps glucose enter cells from the blood. By controlling the level of blood glucose, the symptoms and complications of diabetes are reduced.
The European Commission granted a marketing authorisation valid throughout the European Union for Tresiba on 21 January 2013.